Takeda CEO Christophe Weber announced he will step down in 2026 and be replaced by Julie Kim, president of Takeda’s U.S.

SAN DIEGO, Feb. 4, 2025 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) ("Halozyme") today announced it will release its fourth quarter and full year 2024 financial and operating results ...

Japan's biggest drugmaker Takeda Pharmaceutical posted third-quarter profits on Thursday that trailed analyst estimates but ...

Takeda Pharmaceutical Co.’s board has selected Julie Kim, the head of the company’s US unit, to replace Christophe Weber as ...

Takeda (TOKYO:4502/NYSE:TAK) announced today that its Board of Directors made the decision unanimously to appoint Julie Kim, currently president of Ta ...

Ascentage, backed by Japan's biggest drugmaker Takeda Pharmaceutical (4502.T), opens new tab, is looking to raise $149 million by offering about 7.3 million American depositary shares at $20.34 each.

Among the myriad drugmakers laying out their plans for the future at this year’s J.P. Morgan Healthcare Conference, Takeda said it's laser-focused on six pipeline assets that could each reel in ...